Tvardi Therapeutics (NASDAQ:TVRD) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Tvardi Therapeutics (NASDAQ:TVRD) from a sell rating to a hold rating in a research note issued to investors on Tuesday morning.

TVRD has been the subject of several other research reports. Cantor Fitzgerald lowered shares of Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 13th. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Tvardi Therapeutics in a report on Monday, December 29th. Raymond James Financial downgraded shares of Tvardi Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, October 14th. BTIG Research dropped their price target on shares of Tvardi Therapeutics from $55.00 to $15.00 and set a “buy” rating on the stock in a research note on Monday, October 13th. Finally, Barclays set a $5.00 price objective on Tvardi Therapeutics and gave the stock an “equal weight” rating in a research note on Monday, October 13th. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Tvardi Therapeutics presently has a consensus rating of “Hold” and an average target price of $55.50.

Tvardi Therapeutics Price Performance

TVRD stock opened at $3.93 on Tuesday. Tvardi Therapeutics has a 1 year low of $3.74 and a 1 year high of $43.65. The company has a market cap of $36.86 million, a P/E ratio of -0.41 and a beta of 0.09. The stock’s fifty day moving average price is $4.15 and its 200-day moving average price is $18.50.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.24.

Institutional Trading of Tvardi Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Vestal Point Capital LP purchased a new position in shares of Tvardi Therapeutics during the 3rd quarter valued at $6,508,000. Parkman Healthcare Partners LLC bought a new stake in Tvardi Therapeutics during the third quarter valued at about $2,533,000. Schonfeld Strategic Advisors LLC bought a new stake in Tvardi Therapeutics during the third quarter valued at about $746,000. Squarepoint Ops LLC purchased a new position in shares of Tvardi Therapeutics in the third quarter valued at about $318,000. Finally, Invesco Ltd. bought a new position in shares of Tvardi Therapeutics in the third quarter worth about $3,219,000. 44.66% of the stock is owned by hedge funds and other institutional investors.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.